Dyne Therapeutics to Present at Upcoming Investor Conferences
November 09 2020 - 7:30AM
Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company
focused on advancing innovative life-transforming therapeutics for
people living with genetically driven diseases, today announced
that management will present at upcoming virtual investor
conferences.
Joshua Brumm, president and chief executive officer, and Romesh
Subramanian, Ph.D., chief scientific officer, will participate in
fireside chats at the following:
- Stifel 2020 Virtual Healthcare
Conference; Monday, November 16, 2020 at 10:00 a.m. ET
- Jefferies Virtual London Healthcare
Conference; Thursday, November 19, 2020 at 7:55 a.m. ET
- Piper Sandler 32nd Annual Virtual
Healthcare Conference; pre-recorded and expected to be available
Monday, November 23, 2020
Webcasts and recordings will be available in the Investors &
Media section of Dyne’s website at
https://investors.dyne-tx.com/investors-and-media and accessible
for 90 days following each presentation.
About Dyne Therapeutics
Dyne Therapeutics is building a leading muscle disease company
focused on advancing innovative life-transforming therapeutics for
people living with genetically driven diseases. The Company
utilizes its proprietary FORCE™ platform to overcome the current
limitations of muscle tissue delivery with modern oligonucleotide
therapeutic candidates. Dyne is developing a broad portfolio of
therapeutics for muscle diseases, including lead programs in
myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD)
and facioscapulohumeral muscular dystrophy (FSHD). For more
information, please visit www.dyne-tx.com, and follow us
on Twitter, LinkedIn and Facebook.
Contact:
Dyne TherapeuticsAmy Reillyareilly@dyne-tx.com 857-341-1203
Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart
From Jul 2023 to Jul 2024